Chávez-Castillo Mervin, Nuñez Victoria, Rojas Milagros, Ortega Ángel, Durán Pablo, Pirela Daniela, Marquina María, Cano Clímaco, Chacín Maricarmen, Velasco Manuel, Rojas-Quintero Joselyn, Bermúdez Valmore
Psychiatric Hospital of Maracaibo, Maracaibo, Venezuela
Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, Venezuela
Curr Pharm Des. 2020;26(35):4430-4443. doi: 10.2174/1381612826666200701205132.
At present, the pathologic spectrum of obesity-insulin resistance (IR)-diabetes mellitus (DM) represents not only a pressing matter in public health but also a paramount object of study in biomedical research, as they constitute major risk factors for cardiovascular disease (CVD), and other chronic non-communicable diseases (NCD). Phytotherapy, the use of medicinal herbs (MH) with treatment purposes, offers a wide array of opportunities for innovation in the management of these disorders; mainly as pharmacological research on small molecules accumulates. Several MH has displayed varied mechanisms of action relevant to the pathogenesis of obesity, IR and DM, including immunological and endocrine modulation, reduction of inflammation and oxidative stress (OS), regulation of appetite, thermogenesis and energy homeostasis, sensitisation to insulin function and potentiation of insulin release, among many others. However, the clinical correlates of these molecular phenomena remain relatively uncertain, with only a handful of MH boasting convincing clinical evidence in this regard. This review comprises an exploration of currently available preclinical and clinical research on the role of MH in the management of obesity, IR, and DM.
目前,肥胖-胰岛素抵抗(IR)-糖尿病(DM)的病理谱不仅是公共卫生领域的紧迫问题,也是生物医学研究的首要研究对象,因为它们构成了心血管疾病(CVD)和其他慢性非传染性疾病(NCD)的主要危险因素。植物疗法,即使用药用植物(MH)进行治疗,为这些疾病的管理提供了广泛的创新机会;主要是随着对小分子的药理学研究不断积累。几种MH已显示出与肥胖、IR和DM发病机制相关的多种作用机制,包括免疫和内分泌调节、炎症和氧化应激(OS)的减轻、食欲调节、产热和能量稳态、胰岛素功能致敏和胰岛素释放增强等。然而,这些分子现象的临床相关性仍然相对不确定,只有少数MH在这方面拥有令人信服的临床证据。本综述包括对目前可用的关于MH在肥胖、IR和DM管理中作用的临床前和临床研究的探索。